Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Top Cited Papers
- 1 September 2020
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 396 (10254), 839-852
- https://doi.org/10.1016/s0140-6736(20)31366-0
Abstract
No abstract availableKeywords
Funding Information
- Bristol-Myers Squibb
This publication has 35 references indexed in Scilit:
- Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 LevelsJournal of Clinical Oncology, 2017
- Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cellsScience Translational Medicine, 2016
- The 2016 revision of the World Health Organization classification of lymphoid neoplasmsBlood, 2016
- A Bayesian adaptive phase 1 design to determine the optimal dose and schedule of an adoptive T-cell therapy in a mixed patient populationContemporary Clinical Trials, 2016
- Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivoLeukemia, 2015
- Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL studyBone Marrow Transplantation, 2015
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano ClassificationJournal of Clinical Oncology, 2014
- Current concepts in the diagnosis and management of cytokine release syndromeBlood, 2014
- How I treat elderly patients with diffuse large B-cell lymphomaBlood, 2010
- Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab EraJournal of Clinical Oncology, 2010